| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of Neurosciences (A.S.F., C.T., L.J.T.) and Family and Preventative Medicine (B.B.S., A.C.G.), University of California, San Diego; Mayo Neurology (R.C.P.), Clinic and Foundation, Rochester, MN.
Address correspondence and reprint requests to Dr. Adam S. Fleisher, Alzheimer's Disease Cooperative Study, 8950 Villa La Jolla Drive, Suite C227, La Jolla, CA 92037 afleisher{at}ucsd.edu
Objective: To investigate the neurocognitive measures that best predict progression from amnestic mild cognitive impairment (aMCI) to Alzheimer disease (AD).
Methods: We evaluated 539 participants with aMCI from the Alzheimer's Disease Cooperative Study clinical drug trial of donepezil, vitamin E, or placebo. During the study period of 36 months, 212 aMCI participants progressed to AD. Using progression from aMCI to AD within 36 months as the dependent variable, a generalized linear model was fit to the data using the least absolute shrinkage and selection operator. Independent variables included in this analysis were age, sex, education, APOE-e4 (APOE4) status, family history of dementia, Mini-Mental State Examination score, Digits Backwards (Wechsler Memory Scale), Maze Time and Errors, Number Cancellation, Delayed Recall of Alzheimer's Disease Assessment Scale Word List, New York University Paragraph Recall Test (Immediate and Delayed), Boston Naming Test, Category Fluency, Clock Drawing Test, and the Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS-cog).
Results: The model that best predicted progression from aMCI to AD over 36 months included APOE4 status, the Symbol Digit Modalities Test, Delayed 10-Word List Recall, New York University Paragraph Recall Test (Delayed), and the ADAS-cog total score. When APOE4 was removed from the analysis the resulting model had a similar estimated predictive accuracy as the full model. As determined by cross-validation, the estimated predictive accuracy of the final model was 80%.
Conclusion: Progression from amnestic mild cognitive impairment to Alzheimer disease in this cohort was best determined by combining four common, easily administered, cognitive measures.
This article was previously published as an Expedited E–Pub on February 7, 2007, at www.neurology.org.
Supported by a grant from the National Institute on Aging (UO1 AG10483), The Institute for the Study of Aging, Pfizer Inc., and Eisai Inc.
Disclosure: The authors report no conflicts of interest.
Received July 17, 2006. Accepted in final form January 10, 2007.
This article has been cited by other articles:
|
|
 |
|
  L. Rozzini, B. Vicini Chilovi, E. Bertoletti, M. Conti, I. Delrio, M. Trabucchi, and A. Padovani The Importance of Alzheimer Disease Assessment Scale-cognitive Part in Predicting Progress for Amnestic Mild Cognitive Impairment to Alzheimer Disease J Geriatr Psychiatry Neurol, December 1, 2008; 21(4): 261 - 267. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Bombois, S. Debette, A. Bruandet, X. Delbeuck, C. Delmaire, D. Leys, and F. Pasquier Vascular Subcortical Hyperintensities Predict Conversion to Vascular and Mixed Dementia in MCI Patients Stroke, July 1, 2008; 39(7): 2046 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Fleisher, S. Sun, C. Taylor, C. P. Ward, A. C. Gamst, R. C. Petersen, C. R. Jack Jr, P. S. Aisen, L. J. Thal, and For the Alzheimer's Disease Cooperative Study Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment Neurology, January 15, 2008; 70(3): 191 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Who Progresses from Mild Cognitive Impairment to Alzheimer Disease? Journal Watch Neurology, August 7, 2007; 2007(807): 1 - 1. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
